Anticorps Monoclonal anti-NeutraKine®VEGF165/121

NeutraKine®VEGF165/121 Monoclonal Antibody for Neutralization, ELISA

Hôte / Isotype

Mouse / IgG1

Réactivité testée

Humain

Applications

Neutralization, ELISA

Conjugaison

Non conjugué

Publications

1

CloneNo.

6C3D5

N° de cat : 69025-1-Ig

Synonymes

L VEGFA, MVCD1, Vascular permeability factor, VEGF, VEGF 121, VEGF 165, VEGF A, VEGF121, VEGF165, VEGFA, VPF

---

Galerie de données de validation

• 

  Neutralization experiment of NeutraKine®VEGF165/121 using 69025-1-Ig

  Recombinant human VEGF165 (Cat.NO. HZ-1038) stimulates proliferation of HUVEC (human umbilical vein endothelial) cell line in a dose-dependent manner (blue curve, refer to bottom X-left Y axis). The activity of human VEGF165 (10 ng/mL HZ-1038) is neutralized by mouse anti-human VEGF165/121 monoclonal antibody 69025-1-Ig at serial dose (red curve, refer to top X-right Y axis). The ND50 is typically 0.5-2 μg/mL. The NeutraControl mouse anti-human VEGF165 antibody 69525-1-Ig could recognize human VEGF165 but could not neutralize human VEGF165 acitivity in the range of 0.00244-40 μg/mL (green curve, refer to top X-right Y axis).

• 

  ELISA experiment of Recombinant protein using 69025-1-Ig

  Indirect ELISA was carried out by coating recombinant Human VEGF165 (Cat.NO. HZ-1038) and VEGF121 (Cat.NO. HZ-1204) respectively at 70 ng/well followed by blocking and adding serial diluted VEGF165/121 antibody 69025-1-Ig and VEGF165 antibody 69525-1-Ig respectively. HRP-goat anti-mouse was used for detection. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm. The result suggsts that 69025-1-Ig recognizes both VEGF165 and VEGF121 while 69525-1-Ig recognize VEGF165 only.

---

Neutralization

Applications publiées

• ELISA: See 1 publications below

Informations sur le produit

69025-1-Ig cible NeutraKine®VEGF165/121 dans les applications de Neutralization, ELISA et montre une réactivité avec des échantillons Humain

• Réactivité: Humain
• Réactivité citée: Humain
• Hôte / Isotype: Mouse / IgG1
• Clonalité: Monoclonal
• Type: Anticorps
• Immunogène: human HumankineVEGF165/121 protein HZ-1038
• Nom complet: vascular endothelial growth factor A
• Symbole du gène: VEGFA
• Identification du gène (NCBI): 7422
• Conjugaison: Non conjugué
• Forme: Lyophilized Powder
• Méthode de purification: Purification par protéine G
• Tampon de stockage: PBS stérile.
• Endotoxin: <0.1 EU/μg
• Reconstitution: This product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
• Stability and Storage: Lyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Informations générales

VEGFA, also named as VEGF or VPF, belongs to the PDGF/VEGF growth factor family. It is a growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. VEGFA induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. It binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. Defects in VEGFA are associated with microvascular complications of diabetes type 1 (MVCD1). VEGFA has 17 isoforms with MW from 16 to 45 kDa. Some isoforms have homodimer forms (e.g.; VEGFA189 38 kDa or VEFGA110 34 kDa). VEGF-A exists in at least seven homodimeric isoforms. The monomers consist of 121, 145, 148, 165, 183, 189, or 206 amino acids (PMID:15602010 ).

This antibody is used to neutralize the bioactivity of VEGF165/121. ELISA test suggests that this antibody recognize VEGF165 and VEGF121. According to sequence similarity, it may recognize other isoforms.

Publications

Species	Application	Title
human	ELISA	J Transl Med; Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay; Authors - Xueying Fan